Mohs micrographic surgery (MMS) is considered a generally safe dermatologic surgical procedure with a minimal adverse event profile. However, many patients undergoing MMS are on at least one antithrombotic agent. Antithrombotic agents increase the risk of perioperative hemorrhagic complications, although the increase is mild, and the complications are easily managed in the outpatient setting. Patients undergoing MMS are routinely encouraged to continue clinically indicated antithrombotic therapy in the perioperative period to reduce their risk of severe thrombotic events. MMS practitioners can achieve hemostasis in anticoagulated patients through the use of electrocautery, the application of hemostatic agents, and the judicious use of postoperative pressure dressings. This activity describes the risks, benefits, and recommendations regarding antithrombotic therapy in patients undergoing MMS, reviews the role of intraoperative topical hemostatic agents, and highlights the role of the interprofessional team in caring for these patients.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/149589
- Start Date: 2024-12-01 06:00:00
- End Date: 2024-12-01 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABOHNS - 1.0 Point; Credit Type(s): Self-Assessment (ABOHNS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Facial Plastic & Reconstructive Surgery, Internal Medicine